CMAC National Facility - Drug Product and Secondary Manufacturing
Faster, evidence-based decisions from raw material to finished form
Formulation and process decisions made late or on limited data put development at risk. Scale-up failures, poor solubility and difficult powders delay timelines and consume scarce API. Understanding material properties early provides evidence to support confident manufacturing decisions and drug product characterisation to inform your regulatory submissions.
WHAT SETS US APART
Tablet development, from the first milligram
Our integrated facility supports tablet development across a range of processing routes, from raw material characterisation through granulation, tableting, hot melt extrusion and 3D printing. We bring the equipment, expertise and research depth to help you select and develop the right route for your product.
Scientists who work on your problem, not just your samples
Our teams design studies around your specific formulation and manufacturing challenges, interpreting data, connecting results to your decisions and drawing on the full breadth of CMAC's multidisciplinary expertise.
PROCESSING AND ANALYTICAL PLATFORMS
Seven capabilities. One integrated facility.
-
Material properties shape every downstream decision, so we measure them early. We analyse powder flow, particle size, density, surface, moisture, thermal and rheological behaviour, with in-line PAT to support process selection, formulation and performance prediction.
-
Failures at scale-up often begin with feeding and blending, two operations common to most formulations and routes of administration. Our research focuses on pilot-to-industrial transfer, with systems from grams to kilograms, including the CMAC MicroFeeder for cohesive powders below 10 g/h.
Equipment: CMAC MicroFeeder, Brabender MiniTwin MT-S and FW20, Gericke 200.20, K-Tron; bin, V-, cubic, acoustic, Turbula and Gericke Mini-batch blenders.
-
Fine powders can limit flow, compressibility and uniformity. We use dry, wet and melt granulation to build larger, cohesive granules, with batch and continuous routes and integrated milling.
Equipment: Alexanderwerk BT120 roller compactor, Glatt high-shear wet granulator, Thermo Fisher Process 11 and 16, Retsch MM400 cryomill, Fitzpatrick L1A, Quadromill and Alexanderwerk mills.
-
Tablet development often has to move forward with limited material. We combine tablet presses and compaction simulation with predictive modelling, machine learning and AI, including more predictive tools that require less than 25g of material. Our feed frame simulator measures lubrication sensitivity and its effect on tablet robustness from under 500 g of formulation, avoiding kilo-scale testing. We also run the self-driving Tableting CMC DataFactory®.
Equipment: Korsch XP1 single-punch and hydraulic tablet presses, Huxley Bertram HB50 compaction simulator, Expo FFSim feed frame simulator.
-
Poor solubility can limit bioavailability and stall a promising candidate. We screen raw materials and characterise blends to guide process selection and predict performance, from under 100 mg of API through to pilot-scale continuous HME.
Equipment: HAAKE MiniLab 3 microcompounder, Thermo Fisher Process 11 and 16, pelletiser, laminator.
-
Simple binary formulations have often been considered non-printable. Our filament-free printing opens up this route for them.
Equipment: Filament-free 3D printer, commercial printer.
-
Knowing when a drug releases is only part of the picture. Our multi-modal dissolution and real-time imaging also show how it releases, generating evidence to support your regulatory submissions.
Not sure which platform you need?
Our experts will advise on the best approach for your formulation and process.
APPLICATIONS AND IMPACT
We work across the full spectrum of drug product challenges:
Bioavailability enhancement for poorly soluble drugs via amorphous solid dispersions
Continuous manufacturing process development and batch-to-continuous transfer
Drug product characterisation
Lubrication, feedframe and compaction sensitivity studies at minimal material
Oral solid dosage form development — tablets, granules, capsules and printed forms
Scale-up risk assessment from lab to pilot scale